Go Pro
→ Iran War Shock: What I Was Told In That Private Meeting (From Banyan Hill Publishing) (Ad)tc pixel
NASDAQ:PHVS

Pharvaris Q2 2025 Earnings Report

Pharvaris logo
$32.62 -1.03 (-3.06%)
Closing price 07/29/2026 04:00 PM Eastern
Extended Trading
$32.00 -0.62 (-1.90%)
As of 07/29/2026 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

Pharvaris EPS Results

Actual EPS
-$0.94
Consensus EPS
-$0.87
Beat/Miss
Missed by -$0.07
One Year Ago EPS
N/A

Pharvaris Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Pharvaris Announcement Details

Quarter
Q2 2025
Date
8/12/2025
Time
Before Market Opens
Conference Call Date
Monday, August 11, 2025
Conference Call Time
6:00PM ET

Upcoming Earnings

Pharvaris' Q2 2026 earnings is estimated for Tuesday, August 11, 2026, based on past reporting schedules, with a conference call scheduled on Thursday, August 13, 2026 at 12:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Conference Call Resources

Powered by Quartr

Earnings Documents

Pharvaris' Q2 2025 Press ReleasePress Release
(8-K)

Pharvaris Earnings Headlines

After a 96% 1-Year Run, This Director Sold 37,600 PHVS Shares for $1.3 Million. Is the Rally Over?
July 25, 2026  |  fool.comhttps://www.fool.com/coverage/filings/2026/07/24/after-a-96-1-year-run-this-director-sold-37-600-phvs-shares-for-usd1-3-million-is-the-rally-over/
Publication in Clinical Reviews in Allergy & Immunology Summarizes Decades of Evidence Supporting Bradykinin B2 Receptor as a Validated Therapeutic Target in Bradykinin ...
July 22, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/publication-in-clinical-reviews-in-allergy-immunology-summarizes-decades-of-evidence-supporting-bradykinin-b2-receptor-as-a-validated-therapeutic-target-in-bradykinin-mediated-angioedema-1036350870
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to trigger the next crash. The research firm Bernstein Research said this AI company has the power to crash the global economy for a decade, the CEO just issued a CODE RED in an internal memo warning employees they're dealing with a critical situation, and another company executive even implied they might need a government bailout. The last time I saw something like this was in 2008 when I predicted a stock market meltdown just three weeks before Lehman went under.tc pixel
 |  Paradigm Press (Ad)
Publication in Clinical Reviews in Allergy & Immunology Summarizes Decades of Evidence Supporting Bradykinin B2 Receptor as a Validated Therapeutic Target in Bradykinin-Mediated Angioedema
July 22, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/22/3331202/0/en/publication-in-clinical-reviews-in-allergy-immunology-summarizes-decades-of-evidence-supporting-bradykinin-b2-receptor-as-a-validated-therapeutic-target-in-bradykinin-mediated-angi.html
Pharvaris N.V. (NASDAQ:PHVS) Given Average Recommendation of "Moderate Buy" by Brokerages
July 21, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30912444
Here's why Pharvaris NV (PHVS) is a great momentum stock to buy
July 17, 2026  |  msn.comhttps://www.msn.com/en-us/money/top-stocks/here-s-why-pharvaris-nv-phvs-is-a-great-momentum-stock-to-buy/ar-AA27YUhQ
See More Pharvaris Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Pharvaris? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Pharvaris and other key companies, straight to your email.

About Pharvaris

Pharvaris (NASDAQ:PHVS) is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials. Pharvaris is also developing an on-demand version of its kallikrein inhibitor to provide patients with an acute treatment option. Both candidates represent the company’s effort to offer fully oral alternatives to current injectable therapies.

Founded in 2016 and headquartered in Leiden, the Netherlands, Pharvaris maintains a presence in the United States to support clinical development and regulatory engagement. Since completing its initial public offering on the NASDAQ in 2020, the company has expanded its research partnerships and scaled its operations to prepare for potential commercialization.

Pharvaris is led by an experienced management team with deep expertise in rare disease drug development, medicinal chemistry and clinical operations. The company’s board and advisory committees include professionals with backgrounds in immunology, hematology and regulatory affairs, guiding its strategy toward delivering innovative treatments to patients worldwide.

View Pharvaris Profile
Earnings Tools